The cost-effectiveness of brigatinib in adult patients with ALK inhibitor–naive ALK-positive non–small cell lung cancer from a US perspective

BACKGROUND: The discovery of specific oncogenic drivers in non–small cell lung cancer (NSCLC) has led to the development of highly targeted anaplastic lymphoma kinase tyrosine kinase inhibitors (ALKis). Brigatinib is a next-generation ALKi associated with prolonged progression-free survival in patie...

Descripción completa

Detalles Bibliográficos
Autores principales: Cranmer, Holly, Kearns, Isabella, Young, Melanie, Humphries, Michael J, Trueman, David
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Academy of Managed Care Pharmacy 2022
Materias:
Research
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10373024/
https://www.ncbi.nlm.nih.gov/pubmed/36001099
http://dx.doi.org/10.18553/jmcp.2022.28.9.970

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10373024/
https://www.ncbi.nlm.nih.gov/pubmed/36001099
http://dx.doi.org/10.18553/jmcp.2022.28.9.970

Ejemplares similares